You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Litigation Details for OTSUKA PHARMACEUTICAL CO. LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

✉ Email this page to a colleague

« Back to Dashboard

OTSUKA PHARMACEUTICAL CO. LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

Docket	⤷ Sign Up	Date Filed	2014-10-10
Court	District Court, D. New Jersey	Date Terminated	2016-08-09
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	Plaintiff	Referred To	Karen M. Williams
Parties	TEVA PHARMACEUTICAL INDUSTRIES LTD.
Patents	7,053,092; 8,017,615; 8,580,796; 8,642,600; 8,642,760; 8,759,350
Attorneys	MICHAEL E. PATUNAS
Link to Docket	External link to docket

Small Molecule Drugs cited in OTSUKA PHARMACEUTICAL CO. LTD. v. TEVA PHARMACEUTICALS USA, INC.

The small molecule drugs covered by the patents cited in this case are ⤷ Sign Up and ⤷ Sign Up .

Details for OTSUKA PHARMACEUTICAL CO. LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2014-10-10	1		of U.S. Patent No. 8,580,796 (“the ’796 patent”) and U.S. Patent No. 8,642,760 (“the ’760 patent”), arising… FOR PATENT INFRINGEMENT 11. The U.S. Patent and Trademark Office (“PTO”) issued the ’796 patent on November… of the ’796 patent is attached as Exhibit A. 12. Otsuka is the owner of the ’796 patent by virtue of…The ’796 patent expires on March 25, 2023 (including pediatric exclusivity). 14. The ’796 patent is directed… of the ’760 patent is attached as Exhibit B. 26. Otsuka is the owner of the ’760 patent by virtue of	External link to document
2015-04-16	105		product, U.S. Patent Nos. 5,006,528 (“the ’528 patent”), 7,053,092 (“the ’092 patent”), 8,017,615 (…identifies the ’528 patent, the ’092 patent, the ’615 patent, the ’796 patent, the ’600 patent, the ’760 patent… (“the ’615 patent”), 8,580,796 (“the ’796 patent”), 8,642,600 (“the ’600 patent”), 8,642,760 (“…(“the ’760 patent”), and 8,759,350 (“the ’350 patent”). As the lengthy exclusivity period… for the original compound patent covering Abilify®, the ’528 patent, comes to close on April 20	External link to document
2016-02-18	215		Entry of Summary Judgment Concerning U.S. Patent No. 8,759,350, Certification of Judgment Under Rule 54…2014 9 August 2016 1:14-cv-06398 830 Patent Plaintiff District Court, D. New Jersey	External link to document
>Date Filed	>Document No.	>Description	>Snippet	>Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.